Literature DB >> 710827

Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.

G C Farrell, W G Cooksley, P Hart, L W Powell.   

Abstract

Antipyrine half-life (AP t1/2) was measured in 62 patients with, and 10 control patients without, liver disease to ascertain possible factors which may be useful in identifying patients with abnormal drug metabolism. Antipyrine metabolism was normal or marginally impaired in patients with compensated cirrhosis or acute hepatitis, whereas it was frequently abnormal in those with chronic active hepatitis or advanced alcoholic liver disease. A high degree of correlation was found among AP t1/2 and prothrombin time, hepatic encephalopathy, and ascites. Of patients with severely impaired drug metabolism, 80% had one or more of these features. The severity of histological changes in liver biopsies was of additional help in predicting impaired drug metabolism. Concurrent drug ingestion enhanced antipyrine metabolism in most patients with liver disease as well as in control patients. Inadequate diet was associated with prolongation of AP t1/2, but other environmental factors such as alcohol ingestion, cigarette smoking, and coffee consumption did not affect rates of drug metabolism in patients with liver disease. Consideration of all of the above factors allows qualitative predictions of the rate of hepatic drug metabolism in patients with liver disease, as assessed by the AP t1/2.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 710827

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  16 in total

1.  H3 Propranolol serum levels following lidocaine administration in rats with CCL4 induced liver damage.

Authors:  A Kotsiou; M Tsamouri; S Anagnostopoulou; M Tzivras; E Vairactaris; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

2.  Effects of tobacco smoking and oral contraceptive use on theophylline disposition.

Authors:  M J Gardner; K M Tornatore; W J Jusko; R Kanarkowski
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

3.  Impaired elimination of metronidazole in decompensated chronic liver disease.

Authors:  G Farrell; L Zaluzny; J Baird-Lambert; M Cvejic; N Buchanan
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-17

4.  The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis.

Authors:  H H Tsai; K R Lees; C W Howden; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

5.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.

Authors:  G C Farrell; W G Cooksley; L W Powell
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.

Authors:  M Abei; E Tanaka; N Tanaka; Y Matsuzaki; T Ikegami; A Ishikawa; T Osuga
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

8.  Reduction of paracetamol and aspirin metabolism during viral hepatitis.

Authors:  C Jorup-Rönström; B Beermann; E Wåhlin-Boll; A Melander; S Britton
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

10.  Accuracy and clinical utility of simplified tests of antipyrine metabolism.

Authors:  G C Farrell; L Zaluzny
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.